Lilly warned over Alimta patient booklet

Share this article:
The FDA slapped Eli Lilly with a warning letter over a patient brochure for its oncology treatment Alimta, saying the mailer glossed over the drug's indications and failed to mention its risks.

The Division of Drug Marketing, Advertising and Communications (DDMAC) letter has called the brochure misleading “because it fails to present either approved indication for Alimta.” Namely, for non-small cell lung cancer and, when used in combination with cisplatin, for mesothelioma.

In addition, DDMAC noted, the brochure provided information on types of cancers for which the drug is not indicated, “potentially creating the impression that Alimta is approved to treat a wide range of cancers”—a point the agency called “particularly concerning” because there exist approved treatments for some of the cancers covered.

DDMAC also took issue with the brochure's omission of risk information for pregnant patients, and requested that the company immediately pull the booklet.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.